PMID- 32694998
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy.
PG  - 960
LID - 10.3389/fphar.2020.00960 [doi]
LID - 960
AB  - Dendritic cells (DCs) are the most important antigen-presenting cells that 
      determine cancer immune responses by regulating immune activation and tolerance, 
      especially in the initiation stage of specific responses. Manipulation of DCs to 
      enhance specific antitumor immune response is considered to be a powerful tool 
      for tumor eradication. Nanotechnology, which can incorporate multifunction 
      components and show spatiotemporal control properties, is of great interest and 
      is widely investigated for its ability to improve immune response activity 
      against cancer and even for prevention and avoiding recurrence. In this 
      mini-review, we aim to provide a general view of DC-based immunotherapy, 
      including that involving the promising nanotechnology. Particularly we discuss: 
      (1) manipulation or engineering of DCs for adoptive vaccination, (2) employing 
      DCs as a combination to more existing therapeutics in tumor treatment, and (3) 
      direct modulation of DCs in vivo to enhance antigen presentation efficacy and 
      priming T cells subsequently. We comprehensively discuss the updates on the 
      application of nanotechnology in DC-based immunotherapy and provide some insights 
      on the challenges and opportunities of DC-based immunotherapeutics, including the 
      potential of nanotechnology, against cancers.
CI  - Copyright (c) 2020 Qian, Yang and Cui.
FAU - Qian, Chen
AU  - Qian C
AD  - Department of Pediatrics, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Yang, Li-Jun
AU  - Yang LJ
AD  - Department of Pediatrics, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Cui, Hong
AU  - Cui H
AD  - Department of Pediatrics, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200630
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7338589
OTO - NOTNLM
OT  - antigen delivery
OT  - cancer
OT  - cross-presentation
OT  - dendritic cell
OT  - immunotherapy
OT  - nanotechnology
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
PMCR- 2020/06/30
CRDT- 2020/07/23 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
PHST- 2020/06/30 00:00 [pmc-release]
AID - 10.3389/fphar.2020.00960 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Jun 30;11:960. doi: 10.3389/fphar.2020.00960. eCollection 
      2020.